Form 4: Regeneron Director N. Anthony Coles Acquires Stock and Options

Director N. Anthony Coles reports acquisition of Regeneron stock and options via grant.

Summary

• On January 2, 2025, N. Anthony Coles, a director of Regeneron Pharmaceuticals, acquired 166 shares of common stock and 1,958 non-qualified stock options.
• The stock was acquired at a price of $0.0, and the director now beneficially owns 1,559 shares.
• The non-qualified stock options have an exercise price of $719.37 and expire on January 2, 2035.
• A portion of the options will become exercisable on the date of the Issuer's first annual meeting of shareholders following the date of grant, and the remainder shall become exercisable on the first anniversary of the date of grant.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive as it reflects a director increasing their stake in the company, which is generally seen as a good sign. The acquisition is part of a standard compensation package.

Positives

• The acquisition of stock and options by a director signals confidence in the company's future prospects.

Future Outlook

The vesting schedule of the stock options suggests a long-term commitment by the director to the company's success.

Industry Context

Director stock acquisitions are common in the pharmaceutical industry as part of executive compensation packages, aligning management interests with shareholder value.

Comparison to Industry Standards

• Stock option grants are a typical component of executive compensation in the pharmaceutical industry, often benchmarked against peer companies based on market capitalization and performance.
• The vesting schedules for these options are also standard, designed to incentivize long-term value creation.

Key Dates